医学临床研究
  2025年7月10日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (2): 179-184    DOI: 10.3969/j.issn.1671-7171.2021.02.006
  论著 本期目录 | 过刊浏览 | 高级检索 |
利用生物信息学分析CALHM2在非小细胞肺癌中的表达及临床意义
刘洁1, 黄伟2, 王磊3
1.南华大学附属长沙中心医院,湖南 长沙 410004;
2.中南大学湘雅医院,湖南 长沙 410008;
3.中南大学基础医学院,湖南 长沙 410008
Evaluating Expression and Clinical Value of CALHM2 in Non-small Cell Lung Cancer Through Bioinformatics Data Analysis
LIU Jie, HUANG Wei, WANG Lei
Changsha Central Hospital, University of South China, Changsha, Hunan, 410004, China
全文: PDF (3200 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 基于TCGA及GEO等数据库收录肿瘤高通量数据,分析钙稳态调节家族蛋白2(CALHM2)等CALHMs家族基因在非小细胞肺癌癌(NSCLC)中的表达及临床价值。【方法】 利用Oncomine, GEPIA及UALCAN等在线工具分析和验证CALHMs(CALHM1-6)家族基因在NSCLC的表达水平;利用Human protein Atlas(HPA)分析CALHM2在NSCLC中的蛋白水平和定位;利用GEPIA和UALCAN分析CALHM2表达水平与NSCLC癌患者病理分期、淋巴结转移、p53突变和吸烟史的相关性;利用UALCAN分析CALHM2启动子甲基化水平;利用Kaplan-Meier Plotter分析CALHM2表达水平与NSCLC患者总生存期(OS),首次进展生存期(FP)及进展后生存期(PPS)的相关性;利用LinkedOmics分析NSCLC中与CALHM2表达的显著相关的基因,并利用Metascape进行GO功能富集。【结果】 CALHM2在NSCLC组织中的表达水平显著下调;在NSCLC组织中CALHM2蛋白水平也显著降低。CALHM2表达水平与NSCLC患者病理分期、淋巴结转移、p53突变和吸烟史无显著相关性。Kaplan-Meier Plotter分析结果显示,CALHM2高表达的NSCLC患者的OS和FP均显著优于CALHM2低表达患者。LinckedOmics共筛查得到265个与CALHM2显著相关基因,且Metascape富集分析显示CALHM2相关基因显著富集于淋巴细胞活化和迁移,免疫激活相关过程、细胞因子释放调控等过程。【结论】 在NSCLC中CALHM2表达显著下调,其可作为NSCLC患者预后的判断标志物。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘洁
黄伟
王磊
关键词 癌,非小细胞肺/遗传学癌,非小细胞肺/病理学    
Abstract【Objective】 Based on the high-throughput tumor data in TCGA and GEO, the expression and clinical value of CALHMs family genes such as CALHM2 in non-small cell lung cancer were analyzed. 【Methods】 Using online tools like Oncomine, GEPIA and UALCAN to analyze and verify the expression level of CALHMs (CALHM1-6) family genes in non-small cell lung cancer(NSCLC); Using Human protein Atlas (HPA) to analyze the protein level and location of CALHM2 in NSCLC tissues ; Using GEPIA and UALCAN to analyze the correlations between CALHM2 expression level and pathological stage, lymph node metastasis, p53 mutation and smoking history in patients with NSCLC; Using UALCAN to investigate promoter methylation of CALHM2 in NSCLC; Using Kaplan-Meier Plotter to analyze the relationship between CALHM2 expression level and prognosis of NSCLC including overall survival (OS), first-time progression survival (FP) and post-progression survival (PPS); Using LinkedOmics to analyze the genes that were significantly related to CALHM2 expression in NSCLC; Using Metascape to perform GO function enrichment with CALHM2 correlated genes. 【Results】 The expression of CALHM2 was significantly down-regulated in NSCLC tissue; CALHM2 protein was also significantly reduced in NSCLC tissue. The expression of CALHM2 showed no significant correlation with pathological stage, lymph node metastasis, p53 mutation and smoking history in NSCLC patients. Kaplan-Meier Plotter analysis showed that NSCLC patients with high CALHM2 expression had significantly better OS and FP than those with low CALHM2. LinckedOmics screened a total of 265 genes significantly related to CALHM2, and Metascape enrichment analysis showed that CALHM2 related genes were significantly enriched in lymphocyte activation and migration, immune activation-related processes, and cytokine release regulation. 【Conclusion】 CALHM2 is significantly downregulated in NSCLC and can be used as a prognostic marker for patients with NSCLC.
Key wordsCarcinoma, Non-Small-Cell Lung/GE    Carcinoma, Non-Small-Cell Lung/PA
收稿日期: 2021-01-11     
中图分类号:  R730.26  
通讯作者: *E-mail:leiwang@csu.edu.cn   
引用本文:   
刘洁, 黄伟, 王磊. 利用生物信息学分析CALHM2在非小细胞肺癌中的表达及临床意义[J]. 医学临床研究, 2021, 38(2): 179-184.
LIU Jie, HUANG Wei, WANG Lei. Evaluating Expression and Clinical Value of CALHM2 in Non-small Cell Lung Cancer Through Bioinformatics Data Analysis. JOURNAL OF CLINICAL RESEARCH, 2021, 38(2): 179-184.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.02.006     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I2/179
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn